Literature DB >> 21221606

Adalimumab therapy--a double-edged sword?

Donal Peter O'Leary, Eddie Myers, Sarah Moran, Tara-Jane Browne, Sinead Harney, William O Kirwan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21221606     DOI： 10.1007/s00384-010-1114-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN： 0179-1958            Impact factor:   2.571


× No keyword cloud information.
  4 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

2.  Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.

Authors:  John H Heinzerling; Sergio Huerta
Journal:  Curr Surg       Date:  2006 Sep-Oct

3.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

4.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

Authors:  Frank A Scappaticci; Jamey R Skillings; Scott N Holden; Hans-Peter Gerber; Kathy Miller; Fairooz Kabbinavar; Emily Bergsland; James Ngai; Eric Holmgren; Jiuzhou Wang; Herbert Hurwitz
Journal:  J Natl Cancer Inst       Date:  2007-08-08       Impact factor: 13.506
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.